Article Type
Changed
Fri, 01/04/2019 - 11:09
Display Headline
Current and novel therapeutic approaches in myelodysplastic syndromes

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms with an annual incidence of 4.1 cases per 100,000 Americans. Patients with MDS suffer from chronic cytopenias that may lead to recurrent transfusions, infections, and increased risk for bleeding. They are also at risk for progression to acute myeloid leukemia. Allogeneic hematopoietic cell transplantation is the only potentially curative treatment for MDS, although 3 drugs have been approved by the US Food and Drug Administration for its treatment: lenalidomide, 5-azacitidine, and decitabine.
 

Click on the PDF icon at the top of this introduction to read the full article.

 

Article PDF
Issue
The Journal of Community and Supportive Oncology - 12(7)
Publications
Topics
Page Number
236-249
Legacy Keywords
myelodysplastic syndromes, MDS, acute myeloid leukemia, AML,
Sections
Article PDF
Article PDF

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms with an annual incidence of 4.1 cases per 100,000 Americans. Patients with MDS suffer from chronic cytopenias that may lead to recurrent transfusions, infections, and increased risk for bleeding. They are also at risk for progression to acute myeloid leukemia. Allogeneic hematopoietic cell transplantation is the only potentially curative treatment for MDS, although 3 drugs have been approved by the US Food and Drug Administration for its treatment: lenalidomide, 5-azacitidine, and decitabine.
 

Click on the PDF icon at the top of this introduction to read the full article.

 

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms with an annual incidence of 4.1 cases per 100,000 Americans. Patients with MDS suffer from chronic cytopenias that may lead to recurrent transfusions, infections, and increased risk for bleeding. They are also at risk for progression to acute myeloid leukemia. Allogeneic hematopoietic cell transplantation is the only potentially curative treatment for MDS, although 3 drugs have been approved by the US Food and Drug Administration for its treatment: lenalidomide, 5-azacitidine, and decitabine.
 

Click on the PDF icon at the top of this introduction to read the full article.

 

Issue
The Journal of Community and Supportive Oncology - 12(7)
Issue
The Journal of Community and Supportive Oncology - 12(7)
Page Number
236-249
Page Number
236-249
Publications
Publications
Topics
Article Type
Display Headline
Current and novel therapeutic approaches in myelodysplastic syndromes
Display Headline
Current and novel therapeutic approaches in myelodysplastic syndromes
Legacy Keywords
myelodysplastic syndromes, MDS, acute myeloid leukemia, AML,
Legacy Keywords
myelodysplastic syndromes, MDS, acute myeloid leukemia, AML,
Sections
Citation Override
JCSO 2014;12:236-249
Disallow All Ads
Alternative CME
Article PDF Media